95ACTIVITIES
6ORGS REPRESENTED
30BILLS
Revolving door — covered positions
Federal positions Marc held before / during the 2-year LDA window. This is the credibility signal — who they were inside the building before they started lobbying it.
Legislative Director, Rep. Dave Loebsack
Military Legislative Assistant, Rep. Rick Larsen
Organizations represented
6Orgs whose LD-2 filings list Marc as an active lobbyist, sorted by activity volume.
Pharmaceutical Research and Manufacturers of America (PhRMA)45 activitiesCrossroads Strategies, LLC30 activitiesAssociation of International Certified Professional Accountants (Aicpa)12 activitiesAmerican Association of Colleges of Osteopathic Medicine3 activitiesAssociation for Materials Protection and Performance (Ampp)3 activitiesThe Boeing Company2 activities
Bills they file on
30S. 89111 mentions
S. 52711 mentions
S. 104011 mentions
S. 104111 mentions
S. 109711 mentions
S. 109511 mentions
S. 109611 mentions
H.R. 149210 mentions
S. 83210 mentions
H.R. 73866 mentions
H.R. 29114 mentions
H.R. 23143 mentions
S. 27153 mentions
H.R. 38853 mentions
S. 39893 mentions
+ 15 more bills referenced in their activities
Topics in Filings
56Policy topics Marc files on across all their LD-2 activities.
Drug pricing×22
Federal policies×18
General issues×15
FY2027 Departments of Labor×13
Health and Human Services, and Education, and Related Agencies Appropriations×13
Inflation Reduction Act×12
FY27 National Defense Authorization Act×12
FY27 Department of Defense Appropriations×12
340B drug discount program×11
Importation of biopharmaceuticals×11
International pharmaceutical supply chain×11
PBM reform×11
Show all 56 topics (+44 more) ▾
TRICARE Pharmacy Program×11
Pandemic and All-Hazards Preparedness Act×11
Bipartisan Health Care Act×11
Prescription Pricing for the People Act×11
Drug Competition Enhancement Act×11
Affordable Prescriptions for Patients Act×11
Interagency Patent Coordination and Improvement Act×11
Stop STALLING Act×11
Preserve Access to Affordable Generics and Biosimilars Act×11
Medicare Part B reimbursement×11
Valued-Based Payments×11
Biopharmaceutical innovation and patent policy×11
Bayh-Dole march-in rights policy×11
Delivering Most-Favored-Nation Prescription Drug Pricing to American Patients×10
FY2027 Agriculture×10
Rural Development×10
Food and Drug Administration, and Related Agencies Appropriations×10
CMMI Drug Pricing Demonstration Programs×10
EPIC Act×10
Section 232 tariff investigation on branded pharmaceuticals×10
First Responder Network Authority Reauthorization×6
One Big Beautiful Bill Act×5
FY2027 National Defense Authorization Act×5
Impacting the accounting and auditing profession×4
Accounting STEM Pursuit Act×4
Medicare-funded Graduate Medical Education×3
Osteopathic Funding and Representation×3
FAIR Act×3
Community TEAMS Act×3
Housing and Urban Development, and Related Agencies Appropriations×2
FY2027 Department of Defense Appropriations×2
Antimicrobial resistance×1
Insulin price cap×1
Full-Year Continuing Appropriations and Extensions Act, 2025×1
FY2025 Budget Resolution×1
FY2025 Budget Reconciliation Process×1
All bio-pharmaceutical related provisions×1
FY2026 Transportation×1
ROTOR Act×1
ALERT Act×1
Bridge Corrosion Prevention and Repair Act×1
Next Generation Pipelines Research and Development Act×1
SHIPS for America Act×1
Freedom To Invest in Tomorrow's Workforce Act×1
Issue mix
LDA general-issue codes weighted by activity count.
Defense19
Health Issues14
Medicare/Medicaid11
Copyright/Patent/Trademark11
Trade (domestic/foreign)11
Computer Industry6
Telecommunications6
Accounting4
Education4
Taxation/Internal Revenue Code4